HRP20070432B1 - Gastrorezistentne farmaceutske formulacije koje sadrže rifamicin - Google Patents
Gastrorezistentne farmaceutske formulacije koje sadrže rifamicinInfo
- Publication number
- HRP20070432B1 HRP20070432B1 HRP20070432AA HRP20070432A HRP20070432B1 HR P20070432 B1 HRP20070432 B1 HR P20070432B1 HR P20070432A A HRP20070432A A HR P20070432AA HR P20070432 A HRP20070432 A HR P20070432A HR P20070432 B1 HRP20070432 B1 HR P20070432B1
- Authority
- HR
- Croatia
- Prior art keywords
- pharmaceutical formulations
- formulations containing
- containing rifaximin
- gastroresistant pharmaceutical
- gastroresistant
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- NZCRJKRKKOLAOJ-XRCRFVBUSA-N rifaximin Chemical compound OC1=C(C(O)=C2C)C3=C4N=C5C=C(C)C=CN5C4=C1NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@H](C)[C@@H](OC)\C=C\O[C@@]1(C)OC2=C3C1=O NZCRJKRKKOLAOJ-XRCRFVBUSA-N 0.000 title abstract 2
- 229960003040 rifaximin Drugs 0.000 title abstract 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 abstract 2
- 208000011231 Crohn disease Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 229920000642 polymer Polymers 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Nutrition Science (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IT000123A ITBO20050123A1 (it) | 2005-03-07 | 2005-03-07 | Formulazioni farmaceutiche gastroresistenti contenenti rifaximina |
PCT/EP2006/002022 WO2006094737A2 (en) | 2005-03-07 | 2006-03-06 | Gastroresistant pharmaceutical formulations containing rifaximin |
Publications (2)
Publication Number | Publication Date |
---|---|
HRP20070432A2 HRP20070432A2 (hr) | 2007-11-30 |
HRP20070432B1 true HRP20070432B1 (hr) | 2015-02-13 |
Family
ID=36694343
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20070432AA HRP20070432B1 (hr) | 2005-03-07 | 2007-09-20 | Gastrorezistentne farmaceutske formulacije koje sadrže rifamicin |
Country Status (30)
Country | Link |
---|---|
US (5) | US8568782B2 (hr) |
EP (1) | EP1874273B1 (hr) |
JP (1) | JP4827915B2 (hr) |
KR (1) | KR101157220B1 (hr) |
CN (1) | CN101137350B (hr) |
AU (1) | AU2006222206B2 (hr) |
BR (1) | BRPI0608853B8 (hr) |
CA (1) | CA2595033C (hr) |
CY (1) | CY1114132T1 (hr) |
DK (1) | DK1874273T3 (hr) |
ES (1) | ES2398564T3 (hr) |
HK (1) | HK1115801A1 (hr) |
HR (1) | HRP20070432B1 (hr) |
IL (1) | IL184695A (hr) |
IT (1) | ITBO20050123A1 (hr) |
MA (1) | MA29346B1 (hr) |
MD (1) | MD4180C1 (hr) |
ME (2) | ME00199B (hr) |
MX (1) | MX2007010889A (hr) |
NO (1) | NO340155B1 (hr) |
NZ (1) | NZ556740A (hr) |
PL (1) | PL1874273T3 (hr) |
PT (1) | PT1874273E (hr) |
RS (1) | RS52891B (hr) |
RU (1) | RU2403015C2 (hr) |
SI (1) | SI1874273T1 (hr) |
TN (1) | TNSN07290A1 (hr) |
UA (1) | UA90881C2 (hr) |
WO (1) | WO2006094737A2 (hr) |
ZA (1) | ZA200707396B (hr) |
Families Citing this family (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7048906B2 (en) | 1995-05-17 | 2006-05-23 | Cedars-Sinai Medical Center | Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions |
SI1698630T1 (sl) | 2005-03-03 | 2015-01-30 | Alfa Wassermann S.P.A. | Nove polimorfne oblike rifaksimina, postopki za njihovo pripravo in njihova uporaba v medicinskih pripravkih |
ITBO20050123A1 (it) | 2005-03-07 | 2005-06-06 | Alfa Wassermann Spa | Formulazioni farmaceutiche gastroresistenti contenenti rifaximina |
ITMI20061692A1 (it) | 2006-09-05 | 2008-03-06 | Alfa Wassermann Spa | Uso di polioli per ottenere forme polimorfe stabili di rifaximina |
AU2016203925B2 (en) * | 2007-07-06 | 2016-10-20 | Lupin Limited | Pharmaceutical compositions of rifaximin |
US8974825B2 (en) * | 2007-07-06 | 2015-03-10 | Lupin Limited | Pharmaceutical compositions for gastrointestinal drug delivery |
ES2389358T5 (es) * | 2007-07-06 | 2016-01-19 | Lupin Ltd. | Composiciones farmacéuticas de rifaximina |
WO2009008005A1 (en) * | 2007-07-06 | 2009-01-15 | Lupin Limited | Pharmaceutical compositions of rifaximin |
WO2009047801A1 (en) * | 2007-10-10 | 2009-04-16 | Lupin Limited | Therapeutic combinations and compositions for the treatment of gastrointestinal disorders |
BRPI0908864A2 (pt) | 2008-02-25 | 2018-09-18 | Salix Pharmaceuticals Ltd | formas da rifaximina e usos das mesmas |
US8486956B2 (en) | 2008-02-25 | 2013-07-16 | Salix Pharmaceuticals, Ltd | Forms of rifaximin and uses thereof |
PL2252148T3 (pl) * | 2008-02-26 | 2019-09-30 | Salix Pharmaceuticals, Ltd. | Sposoby leczenia zespołu jelita drażliwego |
US11779571B2 (en) | 2008-02-26 | 2023-10-10 | Salix Pharmaceuticals, Inc. | Methods for treating irritable bowel syndrome (IBS) |
BR112012005627A2 (pt) | 2009-09-13 | 2017-02-21 | Salix Pharmaceuticals Ltd | "uso de rifaximina para preparação de um medicamento para tratar síndrome do intestino irritável (ibs)" |
CZ302789B6 (cs) | 2009-11-25 | 2011-11-09 | Zentiva, K. S. | Zpusob zvýšení rozpustnosti farmaceuticky aktivních látek a cílený (kontrolovaný) transport do streva |
IT1398550B1 (it) * | 2010-03-05 | 2013-03-01 | Alfa Wassermann Spa | Formulazioni comprendenti rifaximina utili per ottenere un effetto prolungato nel tempo |
WO2011110930A2 (en) * | 2010-03-10 | 2011-09-15 | Lupin Limited | Rifaximin ready-to-use suspension |
HUE049986T2 (hu) * | 2010-07-12 | 2020-11-30 | Salix Pharmaceuticals Inc | Rifaximin készítmények és ezek alkalmazásai |
US20170087134A1 (en) * | 2010-07-12 | 2017-03-30 | Salix Pharmaceuticals, Ltd | Formulations of rifaximin and uses thereof |
WO2012035283A1 (en) * | 2010-09-13 | 2012-03-22 | Cipla Limited | Pharmaceutical composition |
IT1403847B1 (it) | 2010-09-22 | 2013-11-08 | Alfa Wassermann Spa | Composizioni farmaceutiche comprendenti rifaximina e loro uso. |
PL2720681T3 (pl) | 2011-06-17 | 2017-05-31 | Evonik Röhm Gmbh | Kompozycja powlekająca odpowiednia do farmaceutycznych lub nutraceutycznych postaci dawkowania |
ITBO20110461A1 (it) | 2011-07-29 | 2013-01-30 | Alfa Wassermann Spa | Composizioni farmaceutiche comprendenti rifaximina, processi per la loro preparazione e loro uso nel trattamento di infezioni vaginali. |
ITBO20120368A1 (it) * | 2012-07-06 | 2014-01-07 | Alfa Wassermann Spa | Composizioni comprendenti rifaximina e amminoacidi, cristalli di rifaximina derivanti da tali composizioni e loro uso. |
US9956310B2 (en) | 2012-07-18 | 2018-05-01 | Jeannette Martello | Time indicator tampon |
DE102012024434A1 (de) * | 2012-12-14 | 2014-06-18 | Regalismons S.A. | Verstärkung der entschäumenden Wirkung von Polysiloxanen, zugehöriger Zusammensetzungen und Lösungen |
MX2015014307A (es) * | 2013-04-12 | 2015-12-08 | Alfa Wassermann Spa | Administracion de farmacos antiinflamatorios no esteroidales y composiciones, metodos y sistemas relacionados. |
CN103340856A (zh) * | 2013-07-09 | 2013-10-09 | 荣港生技医药科技(北京)有限公司 | 一种利福昔明药物组合物及其制备方法 |
TWI664164B (zh) | 2014-02-13 | 2019-07-01 | 美商英塞特控股公司 | 作為lsd1抑制劑之環丙胺 |
SG10201806849WA (en) | 2014-02-13 | 2018-09-27 | Incyte Corp | Cyclopropylamines as lsd1 inhibitors |
US9474699B2 (en) * | 2014-03-31 | 2016-10-25 | Johnson & Johnson Consumer Inc. | Compostions and methods for enhancing the topical application of a basic benefit agent |
PL3546464T3 (pl) | 2014-05-12 | 2020-11-02 | Alfasigma S.P.A. | Sposób wytwarzania i zastosowanie postaci krystalicznej Tau rifaksyminy solwatowanej z DEGME |
WO2016007722A1 (en) | 2014-07-10 | 2016-01-14 | Incyte Corporation | Triazolopyridines and triazolopyrazines as lsd1 inhibitors |
JP6995623B2 (ja) | 2015-04-03 | 2022-01-14 | インサイト・コーポレイション | Lsd1阻害剤としてのヘテロ環式化合物 |
TWI765860B (zh) | 2015-08-12 | 2022-06-01 | 美商英塞特公司 | Lsd1抑制劑之鹽 |
US9668991B1 (en) | 2015-12-09 | 2017-06-06 | International Business Machines Corporation | SCFA colonic composition |
EP3536311B1 (en) | 2016-03-24 | 2021-12-22 | Sandoz AG | Storage stable composition comprising rifaximin alpha |
PL3434265T3 (pl) * | 2016-03-24 | 2021-12-13 | Sandoz Ag | Kompozycja farmaceutyczna zawierająca rifaksyminę alfa i delta |
JP7027412B2 (ja) | 2016-09-30 | 2022-03-01 | サリックス ファーマスーティカルズ,インコーポレーテッド | リファキシミンの固体分散体の形態 |
MX2018010065A (es) | 2017-04-26 | 2019-02-07 | Sandoz Ag | Forma de dosificacion oral que comprende rifaximina en forma beta. |
US10968200B2 (en) | 2018-08-31 | 2021-04-06 | Incyte Corporation | Salts of an LSD1 inhibitor and processes for preparing the same |
WO2020208140A1 (en) | 2019-04-12 | 2020-10-15 | Sandoz Ag | Rifaximin-containing granules |
CN114401721A (zh) * | 2019-09-24 | 2022-04-26 | 博士医疗爱尔兰有限公司 | 利福昔明液体制剂 |
JP2023531268A (ja) * | 2020-06-26 | 2023-07-21 | バウシュ ヘルス アイルランド リミテッド | 標的化放出リファキシミン組成物 |
US11944633B2 (en) | 2022-02-17 | 2024-04-02 | Woolsey Pharmaceuticals, Inc. | Oral formulations of fasudil with ion exchange resin |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0616808A1 (en) * | 1993-03-23 | 1994-09-28 | ALFA WASSERMANN S.p.A. | Use of rifaximin and pharmaceutical compositions containing it in the treatment of gastric dyspepsia caused by helicobacter pylori |
US20020039599A1 (en) * | 1995-05-17 | 2002-04-04 | Lin Henry C. | Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions |
US20040170617A1 (en) * | 2000-06-05 | 2004-09-02 | Finegold Sydney M. | Method of treating diseases associated with abnormal gastrointestinal flora |
US20050008652A1 (en) * | 1999-08-11 | 2005-01-13 | Cedars-Sinai Medical Center | Method of diagnosing irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth |
Family Cites Families (72)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2043847A1 (hr) | 1969-05-30 | 1971-02-19 | Takeda Chemical Industries Ltd | |
US4206677A (en) | 1978-07-17 | 1980-06-10 | Teledyne Industries, Inc. | Pedal actuator for electronic player piano |
IT1154655B (it) | 1980-05-22 | 1987-01-21 | Alfa Farmaceutici Spa | Derivati imidazo-rifamicinici metodi per la loro preparazione e loro uso come sostanza ad azione antibatterica |
DK150008C (da) * | 1981-11-20 | 1987-05-25 | Benzon As Alfred | Fremgangsmaade til fremstilling af et farmaceutisk oralt polydepotpraeparat |
IT1199374B (it) | 1984-05-15 | 1988-12-30 | Alfa Farmaceutici Spa | Processo per la preparazione di pirido-imidazo-rifamicine |
US5356625A (en) * | 1986-08-28 | 1994-10-18 | Enzacor Properties Limited | Microgranular preparation useful in the delivery of biologically active materials to the intestinal regions of animals |
GB2253346A (en) * | 1991-02-22 | 1992-09-09 | John Rhodes | Delayed release oral dosage forms for treatment of intestinal disorders |
IT1245907B (it) | 1991-05-17 | 1994-10-25 | Alfa Wassermann Spa | Uso dei glicosaminoglicani nel trattamento della nefropatia diabetica e della neuropatia diabetica. |
IT1253711B (it) * | 1991-12-17 | 1995-08-23 | Alfa Wassermann Spa | Formulazioni farmaceutiche vaginali contenenti rifaximin e loro uso nel trattamento delle infezioni vaginali |
US5549911A (en) * | 1994-01-14 | 1996-08-27 | Laboratoires Des Produits Ethiques Ethypharm | Galenic form of 5-nitromidazole derivatives which is effective for the treatment of parasitoses and infections of the entire gastrointestinal tract |
US5592021A (en) * | 1995-04-26 | 1997-01-07 | Martin Marietta Corporation | Clamp for securing a power device to a heatsink |
US5840332A (en) * | 1996-01-18 | 1998-11-24 | Perio Products Ltd. | Gastrointestinal drug delivery system |
DE69739394D1 (de) | 1996-10-16 | 2009-06-18 | Napo Pharmaceuticals Inc | Enteral-formulierungen von proanthocyanidzusammensetzungen gegen diarrhöe |
IT1290679B1 (it) | 1997-02-14 | 1998-12-10 | Alfa Wassermann Spa | Uso della rifaximina e delle composizioni farmaceutiche che la contengono nel trattamento della diarrea da criptosporidiosi. |
FR2772047B1 (fr) | 1997-12-05 | 2004-04-09 | Ct Nat D Etudes Veterinaires E | Sequence genomique et polypeptides de circovirus associe a la maladie de l'amaigrissement du porcelet (map), applications au diagnostic et a la prevention et/ou au traitement de l'infection |
US6770623B1 (en) | 1997-12-09 | 2004-08-03 | Eli Lilly And Company | Stabilized teriparatide solutions |
US20030059471A1 (en) * | 1997-12-15 | 2003-03-27 | Compton Bruce Jon | Oral delivery formulation |
US6090411A (en) * | 1998-03-09 | 2000-07-18 | Temple University | Monolithic tablet for controlled drug release |
DE19848260C2 (de) * | 1998-10-20 | 2002-01-17 | Fumapharm Ag Muri | Fumarsäure-Mikrotabletten |
US20010055613A1 (en) * | 1998-10-21 | 2001-12-27 | Beth A. Burnside | Oral pulsed dose drug delivery system |
US20030157174A1 (en) * | 2000-03-23 | 2003-08-21 | Takayuki Tsukuda | Enteric granular preparations of hardly water soluble drugs characterized by containing water-repellent component |
DE20220604U1 (de) * | 2001-07-27 | 2004-02-26 | Yamanouchi Pharmaceutical Co., Ltd. | Zusammensetzung, enthaltend feine Partikel zur Langzeitfreisetzung für schnell in der Mundhöhle zerfallende Tabletten |
US8101209B2 (en) | 2001-10-09 | 2012-01-24 | Flamel Technologies | Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles |
WO2004004696A1 (en) * | 2002-07-05 | 2004-01-15 | Temrel Inc. | Controlled release composition |
ITMI20032144A1 (it) | 2003-11-07 | 2005-05-08 | Alfa Wassermann Spa | Forme polimorfe di rifaximina, processi per ottenerle e |
US7902206B2 (en) | 2003-11-07 | 2011-03-08 | Alfa Wassermann, S.P.A. | Polymorphic forms α, β and γ of rifaximin |
US7906542B2 (en) | 2004-11-04 | 2011-03-15 | Alfa Wassermann, S.P.A. | Pharmaceutical compositions comprising polymorphic forms α, β, and γ of rifaximin |
US7923553B2 (en) | 2003-11-07 | 2011-04-12 | Alfa Wassermann, S.P.A. | Processes for the production of polymorphic forms of rifaximin |
US20080262024A1 (en) | 2003-11-07 | 2008-10-23 | Giuseppe Claudio Viscomi | Rifaximin compositions and method of use |
US20050196418A1 (en) | 2004-03-04 | 2005-09-08 | Yu Ruey J. | Bioavailability and improved delivery of alkaline pharmaceutical drugs |
MX2007000632A (es) | 2004-07-16 | 2007-03-30 | Cipla Ltd | Composicion antihistaminica. |
US20060210492A1 (en) | 2005-03-02 | 2006-09-21 | Kodsi Robert E | Use of rifaximin for treatment and prevention of periodontal conditions |
US8003118B2 (en) | 2005-03-02 | 2011-08-23 | Kodsi Robert E | Use of rifaximin for the prevention of aspiration pneumonia and/or sepsis |
US20060210483A1 (en) | 2005-03-02 | 2006-09-21 | Kodsi Robert E | Non-systemic antibiotic formulations and related method of use and treatment of upper respiratory infections |
SI1698630T1 (sl) | 2005-03-03 | 2015-01-30 | Alfa Wassermann S.P.A. | Nove polimorfne oblike rifaksimina, postopki za njihovo pripravo in njihova uporaba v medicinskih pripravkih |
ITBO20050123A1 (it) | 2005-03-07 | 2005-06-06 | Alfa Wassermann Spa | Formulazioni farmaceutiche gastroresistenti contenenti rifaximina |
JP5331487B2 (ja) | 2006-03-09 | 2013-10-30 | サリックス ファーマシューティカルズ, インコーポレイテッド | リファキシム抗直腸機能不全製剤 |
US20070254050A1 (en) | 2006-05-01 | 2007-11-01 | Quart Barry D | Method for treatment of diarrhea-predominant irritable bowel syndrome |
AU2007248183B2 (en) | 2006-05-01 | 2013-08-01 | Napo Pharmaceuticals, Inc. | Compositions and methods for treating or preventing inflammatory bowel disease, familial adenomatous polyposis and colon cancer |
BRPI0714724A8 (pt) | 2006-08-02 | 2018-04-10 | Salix Pharmaceuticals Inc | métodos para tratar enterite, para proteger contra a enterite, contra a lesão à mucosa do cólon e contra a inflamação colorretal induzidas pela radiação, para tratar enterite em um indivíduo ou monitorar o progresso de um indivíduo que é tratado de enterite, para selecionar um indivíduo para o tratamento de enterite, e, para tratar diarréia profilaticamente. |
ITMI20061692A1 (it) | 2006-09-05 | 2008-03-06 | Alfa Wassermann Spa | Uso di polioli per ottenere forme polimorfe stabili di rifaximina |
WO2009008005A1 (en) | 2007-07-06 | 2009-01-15 | Lupin Limited | Pharmaceutical compositions of rifaximin |
ES2389358T5 (es) | 2007-07-06 | 2016-01-19 | Lupin Ltd. | Composiciones farmacéuticas de rifaximina |
US8974825B2 (en) | 2007-07-06 | 2015-03-10 | Lupin Limited | Pharmaceutical compositions for gastrointestinal drug delivery |
WO2009047801A1 (en) | 2007-10-10 | 2009-04-16 | Lupin Limited | Therapeutic combinations and compositions for the treatment of gastrointestinal disorders |
AU2008312464A1 (en) | 2007-10-17 | 2009-04-23 | Govt. Of The U.S.A., As Represented By The Secretary Department Of Health And Human Services | Novel therapeutic targets in bowel disease |
PL2252148T3 (pl) | 2008-02-26 | 2019-09-30 | Salix Pharmaceuticals, Ltd. | Sposoby leczenia zespołu jelita drażliwego |
DK2294012T3 (da) | 2008-05-07 | 2014-10-06 | Salix Pharmaceuticals Ltd | Administration af et tarmrensemiddel og et antibiotika til behandlingen af tarmsygdom |
PT2327407E (pt) | 2008-09-26 | 2014-09-10 | Aska Pharm Co Ltd | Agentes profiláticos e/ou terapêuticos para desordens gastrointestinais funcionais |
US20100317681A1 (en) | 2009-06-15 | 2010-12-16 | Salix Pharmaceuticals, Ltd. | Modulation of systemic exposure to rifaximin |
US7928115B2 (en) | 2008-10-02 | 2011-04-19 | Salix Pharmaceuticals, Ltd. | Methods of treating travelers diarrhea and hepatic encephalopathy |
WO2010044093A1 (en) | 2008-10-16 | 2010-04-22 | Strides Arcolab Limited | Formulations containing rifaximin |
BRPI1008058A8 (pt) | 2009-02-11 | 2018-03-27 | Cedars Sinai Medical Center | uso de antibióticos para reduzir a probabilidade de desenvolver síndrome do intestino irritável pós-infecciosa |
IT1397617B1 (it) | 2009-04-20 | 2013-01-18 | Alfa Wassermann Spa | Nuovi derivati della rifamicina |
EP2440210A4 (en) | 2009-06-12 | 2014-01-29 | Meritage Pharma Inc | METHOD FOR THE TREATMENT OF STOMACH DARM DISEASES |
CA2765577A1 (en) | 2009-06-15 | 2010-12-23 | William Forbes | Modulation of systemic exposure to rifaximin |
BR112012005627A2 (pt) | 2009-09-13 | 2017-02-21 | Salix Pharmaceuticals Ltd | "uso de rifaximina para preparação de um medicamento para tratar síndrome do intestino irritável (ibs)" |
NZ598716A (en) | 2009-10-26 | 2014-08-29 | Borody Thomas J | Novel enteric combination therapy |
KR102456997B1 (ko) | 2009-10-27 | 2022-10-19 | 루핀 리미티드 | 리팍시민의 고형 분산물 |
MX2012005882A (es) | 2009-11-23 | 2012-10-09 | Cipla Ltd | Composicion en espuma topica. |
WO2011061519A2 (en) | 2009-11-23 | 2011-05-26 | Cipla Limited | Topical foam composition |
CN101773465B (zh) | 2010-01-19 | 2012-11-07 | 南京泛太化工医药研究所 | 以氨基酸为稳定剂的聚合物胶束载药系统 |
EP2536282A4 (en) | 2010-02-18 | 2013-07-03 | Salix Pharmaceuticals Ltd | METHOD FOR THE TREATMENT OF INFECTIONS |
IT1398550B1 (it) | 2010-03-05 | 2013-03-01 | Alfa Wassermann Spa | Formulazioni comprendenti rifaximina utili per ottenere un effetto prolungato nel tempo |
WO2011110930A2 (en) | 2010-03-10 | 2011-09-15 | Lupin Limited | Rifaximin ready-to-use suspension |
HUE049986T2 (hu) | 2010-07-12 | 2020-11-30 | Salix Pharmaceuticals Inc | Rifaximin készítmények és ezek alkalmazásai |
WO2012035283A1 (en) | 2010-09-13 | 2012-03-22 | Cipla Limited | Pharmaceutical composition |
IT1403847B1 (it) | 2010-09-22 | 2013-11-08 | Alfa Wassermann Spa | Composizioni farmaceutiche comprendenti rifaximina e loro uso. |
WO2012076832A1 (en) | 2010-12-09 | 2012-06-14 | Cipla Limited | Suppositories comprising rifaximin |
ITBO20110461A1 (it) | 2011-07-29 | 2013-01-30 | Alfa Wassermann Spa | Composizioni farmaceutiche comprendenti rifaximina, processi per la loro preparazione e loro uso nel trattamento di infezioni vaginali. |
CA2854380A1 (en) | 2011-11-02 | 2013-05-10 | Salix Pharmaceuticals, Ltd. | Methods for treating irritable bowel syndrome (ibs) and infections |
CN105579458A (zh) | 2013-05-17 | 2016-05-11 | 萨利克斯药品公司 | 在正电子发射断层摄影术(pet)扫描中使用利福昔明的方法 |
-
2005
- 2005-03-07 IT IT000123A patent/ITBO20050123A1/it unknown
-
2006
- 2006-03-06 CA CA2595033A patent/CA2595033C/en active Active
- 2006-03-06 AU AU2006222206A patent/AU2006222206B2/en active Active
- 2006-03-06 PT PT67232264T patent/PT1874273E/pt unknown
- 2006-03-06 EP EP06723226A patent/EP1874273B1/en active Active
- 2006-03-06 BR BRPI0608853A patent/BRPI0608853B8/pt active IP Right Grant
- 2006-03-06 MD MDA20070267A patent/MD4180C1/ro active IP Right Grant
- 2006-03-06 ES ES06723226T patent/ES2398564T3/es active Active
- 2006-03-06 ME MEP-2008-311A patent/ME00199B/me unknown
- 2006-03-06 WO PCT/EP2006/002022 patent/WO2006094737A2/en active Application Filing
- 2006-03-06 SI SI200631547T patent/SI1874273T1/sl unknown
- 2006-03-06 ZA ZA200707396A patent/ZA200707396B/xx unknown
- 2006-03-06 US US11/814,628 patent/US8568782B2/en active Active
- 2006-03-06 PL PL06723226T patent/PL1874273T3/pl unknown
- 2006-03-06 RS RS20070365A patent/RS52891B/en unknown
- 2006-03-06 KR KR1020077022318A patent/KR101157220B1/ko active IP Right Grant
- 2006-03-06 RU RU2007136428/15A patent/RU2403015C2/ru active
- 2006-03-06 ME MEP-311/08A patent/MEP31108A/hr unknown
- 2006-03-06 CN CN2006800075957A patent/CN101137350B/zh active Active
- 2006-03-06 NZ NZ556740A patent/NZ556740A/en unknown
- 2006-03-06 DK DK06723226.4T patent/DK1874273T3/da active
- 2006-03-06 MX MX2007010889A patent/MX2007010889A/es active IP Right Grant
- 2006-03-06 JP JP2008500103A patent/JP4827915B2/ja active Active
- 2006-06-03 UA UAA200708881A patent/UA90881C2/uk unknown
-
2007
- 2007-07-18 IL IL184695A patent/IL184695A/en active IP Right Grant
- 2007-07-24 TN TNP2007000290A patent/TNSN07290A1/en unknown
- 2007-09-20 HR HRP20070432AA patent/HRP20070432B1/hr active IP Right Grant
- 2007-09-26 MA MA30246A patent/MA29346B1/fr unknown
- 2007-10-08 NO NO20075046A patent/NO340155B1/no unknown
-
2008
- 2008-06-04 HK HK08106217.6A patent/HK1115801A1/xx unknown
-
2010
- 2010-01-28 US US12/695,945 patent/US20100330129A1/en not_active Abandoned
-
2013
- 2013-03-29 CY CY20131100263T patent/CY1114132T1/el unknown
- 2013-10-02 US US14/044,844 patent/US10285944B2/en active Active
- 2013-12-04 US US14/097,222 patent/US20140186450A1/en not_active Abandoned
-
2019
- 2019-04-09 US US16/379,709 patent/US20200000726A1/en not_active Abandoned
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0616808A1 (en) * | 1993-03-23 | 1994-09-28 | ALFA WASSERMANN S.p.A. | Use of rifaximin and pharmaceutical compositions containing it in the treatment of gastric dyspepsia caused by helicobacter pylori |
US20020039599A1 (en) * | 1995-05-17 | 2002-04-04 | Lin Henry C. | Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions |
US20050008652A1 (en) * | 1999-08-11 | 2005-01-13 | Cedars-Sinai Medical Center | Method of diagnosing irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth |
US6861053B1 (en) * | 1999-08-11 | 2005-03-01 | Cedars-Sinai Medical Center | Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth |
US20040170617A1 (en) * | 2000-06-05 | 2004-09-02 | Finegold Sydney M. | Method of treating diseases associated with abnormal gastrointestinal flora |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20070432B1 (hr) | Gastrorezistentne farmaceutske formulacije koje sadrže rifamicin | |
WO2004041195A3 (en) | Pharmaceutical formulations targeting specific regions of the gastrointestinal tract | |
CA3094580C (en) | Oral formulations of cytidine analogs and methods of use thereof | |
CY1113882T1 (el) | Φαρμακευτικες συνθεσεις κυκλοσπορινης (cyclosporin) | |
PL1909843T3 (pl) | Przeciwnowotworowe biokoniugaty kwasu hialuronowego lub jego pochodne otrzymane przez pośrednie sprzęganie chemiczne i ich zastosowanie w dziedzinie farmacji | |
ATE380023T1 (de) | Orale feste pharmazeutische zusammensetzungen zur ph-abhängig mehrphasigen freisetzung | |
WO2007100902A3 (en) | Acryloyloxyethylphosphorylcholine containing polymer conjugates and their preparation | |
WO2008039218A3 (en) | Inhibitors of bruton's tyrosine kinase | |
WO2006014673A3 (en) | Insulin-oligomer conjugates, formulations and uses thereof | |
WO2005072061A3 (en) | Conjugates for cancer therapy and diagnosis | |
WO2008137758A3 (en) | Amino acid lipids and uses thereof | |
EP2422803A3 (en) | Compositions comprising human embryonic stem cells and their derivatives, methods of use, and methods of preparation | |
WO2004112711A3 (en) | Oral extended-release composition | |
ZA200809864B (en) | Pharmaceutical formulations for the sustained release of active ingredients(s), as well as their applications, especially therapeutic | |
MX2009011316A (es) | Derivados del acido lipoico. | |
DE602008000786D1 (de) | 1,2,4,5-Tetrahydro-3H-Benzazepinderivate, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zusammensetzungen | |
UA90893C2 (ru) | Пероральная дозированная форма производных гемцитабина | |
MY139086A (en) | Use of debranched starch in extrusion-spheronization pharmaceutical pellets | |
HK1120417A1 (en) | Stable nanoparticle formulations | |
HK1125041A1 (en) | Pharmaceutical formulations comprising dextran with molecular weight of 1.0-100kda and processes for their preparation | |
TR200806300A2 (tr) | Çözünürlük artırıcı farmasötlk formulasyon | |
ATE430748T1 (de) | Imidazo (1,2-a)pyridin-3-ylessigsäurehydrazide, herstellungsverfahren dafür und pharmazeutische verwendungen davon | |
MY150692A (en) | Gastroresistant pharmaceutical formulations containing rifaximin | |
JO2946B1 (en) | Improved antibiotic absorption rate | |
DE602005003161D1 (de) | 4-Oxo-4,6,7,8-tetrahydropyrroloi1,2-a pyrazin-6-carboxamid-Derivate, Vefahren zu deren Herstellung sowie diese enthaltende pharmazeutische Zusammensetzungen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A1OB | Publication of a patent application | ||
AIPI | Request for the grant of a patent on the basis of a substantive examination of a patent application | ||
B1PR | Patent granted | ||
PNAN | Change of the applicant name, address/residence |
Owner name: ALFASIGMA S.P.A., IT |
|
ODRP | Renewal fee for the maintenance of a patent |
Payment date: 20190222 Year of fee payment: 14 |
|
ODRP | Renewal fee for the maintenance of a patent |
Payment date: 20200203 Year of fee payment: 15 |
|
ODRP | Renewal fee for the maintenance of a patent |
Payment date: 20210218 Year of fee payment: 16 |
|
ODRP | Renewal fee for the maintenance of a patent |
Payment date: 20220303 Year of fee payment: 17 |
|
ODRP | Renewal fee for the maintenance of a patent |
Payment date: 20230126 Year of fee payment: 18 |
|
ODRP | Renewal fee for the maintenance of a patent |
Payment date: 20240130 Year of fee payment: 19 |